Gavi aims to use $600 million in soon-to-be-restored U.S. funding for malaria and other vaccination efforts. The global vaccine group also stated it is meeting U.S. conditions to phase out thimerosal in its vaccines, a key concern raised by U.S. officials.
The restoration of U.S. funding is crucial for Gavi's ability to combat diseases like malaria and maintain essential vaccination programs, impacting global health initiatives and potentially influencing the broader U.S. approach to international health aid.
The global vaccine alliance Gavi intends to utilize $600 million in U.S. funding, which is expected to be restored soon, to support malaria prevention and other vaccination programs. This plan aligns with conditions set by U.S. officials, including the phasing out of the preservative thimerosal in certain vaccines.
Previously, this $600 million, approved by Congress for 2025 and 2026, was withheld by U.S. Health Secretary Robert F. Kennedy Jr. due to unspecified safety concerns. Gavi has stated that its board will determine the final allocation of these funds, with malaria initiatives being a likely priority given a significant budget shortfall previously warned about.
U.S. Secretary of State Marco Rubio recently signaled a shift, suggesting it was time to re-engage and that the funds would be disbursed shortly, though a specific date was not provided. The future of long-term U.S. funding for Gavi remains uncertain.
A Gavi spokesperson emphasized the critical need for secured appropriations from Congress and other donors to maintain its malaria work, preventive campaigns for diseases like cholera, and global vaccine stockpiles. The U.S. funding is also expected to accelerate Gavi's transition to vaccines that do not contain thimerosal, a move Gavi had already planned as part of its commitment to providing effective tools.
Pick the topics you care about. Get only what matters, on your cadence.